Literature DB >> 20686872

A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder.

Dan J Stein1, David S Baldwin, Borwin Bandelow, Carlos Blanco, Leonardo F Fontenelle, Sing Lee, Hisato Matsunaga, David Osser, Murray B Stein, Michael van Ameringen.   

Abstract

A growing evidence base on the management of social anxiety disorder has yielded many meta-analyses and guidelines on the pharmacotherapy of this clinically important condition. We aimed to update a pharmacotherapy algorithm for the treatment of social anxiety disorder that was developed to be concise and user friendly and that was addressed to the primary care practitioner in particular. The updated algorithm attempts to summarize succinctly the recent literature in this area, as well as to include the views of an international panel of experts with diverse experience. The algorithm comprises eight sequential steps, beginning with those focused on diagnosis and initiating treatment and ending with the management of the treatment-refractory patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686872     DOI: 10.1007/s11920-010-0140-8

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  50 in total

1.  What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

Authors:  Borwin Bandelow; David S Baldwin; Ornah T Dolberg; Henning Friis Andersen; Dan J Stein
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

2.  An open-label trial of risperidone augmentation for refractory anxiety disorders.

Authors:  Naomi M Simon; Elizabeth A Hoge; Diana Fischmann; John J Worthington; Kelly M Christian; Gustavo Kinrys; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2006-03       Impact factor: 4.384

3.  Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.

Authors:  Kenneth A Kobak; John H Greist; James W Jefferson; David J Katzelnick
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

Review 4.  Size and burden of social phobia in Europe.

Authors:  Lydia Fehm; Antoine Pelissolo; Tomas Furmark; Hans-Ulrich Wittchen
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

5.  The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation.

Authors:  S Pallanti; L Quercioli; A Rossi; A Pazzagli
Journal:  J Clin Psychiatry       Date:  1999-12       Impact factor: 4.384

6.  Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.

Authors:  John J Worthington; Gustavo Kinrys; Lisa E Wygant; Mark H Pollack
Journal:  Int Clin Psychopharmacol       Date:  2005-01       Impact factor: 1.659

7.  A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Authors:  Carlos Blanco; Richard G Heimberg; Franklin R Schneier; David M Fresco; Henian Chen; Cynthia L Turk; Donna Vermes; Brigette A Erwin; Andrew B Schmidt; Harlan R Juster; Raphael Campeas; Michael R Liebowitz
Journal:  Arch Gen Psychiatry       Date:  2010-03

8.  Phenelzine efficacy in refractory social anxiety disorder: a case series.

Authors:  Trond F Aarre
Journal:  Nord J Psychiatry       Date:  2003       Impact factor: 2.202

Review 9.  WCA recommendations for the long-term treatment of social phobia.

Authors:  Michael Van Ameringen; Christer Allgulander; Borwin Bandelow; John H Greist; Eric Hollander; Stuart A Montgomery; David J Nutt; Ahmed Okasha; Mark H Pollack; Dan J Stein; Richard P Swinson
Journal:  CNS Spectr       Date:  2003-08       Impact factor: 3.790

10.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.

Authors:  Jonathan R T Davidson; Edna B Foa; Jonathan D Huppert; Francis J Keefe; Martin E Franklin; Jill S Compton; Ning Zhao; Kathryn M Connor; Thomas R Lynch; Kishore M Gadde
Journal:  Arch Gen Psychiatry       Date:  2004-10
View more
  9 in total

Review 1.  Pharmacotherapy of anxiety disorders: a critical review.

Authors:  Nastassja Koen; Dan J Stein
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

2.  Optimal treatment of social phobia: systematic review and meta-analysis.

Authors:  John Canton; Kate M Scott; Paul Glue
Journal:  Neuropsychiatr Dis Treat       Date:  2012-05-03       Impact factor: 2.570

3.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

4.  Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment.

Authors:  Naoki Yoshinaga; Tomihisa Niitsu; Hideki Hanaoka; Yasunori Sato; Fumiyo Ohshima; Satoshi Matsuki; Osamu Kobori; Michiko Nakazato; Akiko Nakagawa; Masaomi Iyo; Eiji Shimizu
Journal:  BMJ Open       Date:  2013-02-13       Impact factor: 2.692

5.  A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial.

Authors:  Naoki Yoshinaga; Fumiyo Ohshima; Satoshi Matsuki; Mari Tanaka; Tomomi Kobayashi; Hanae Ibuki; Kenichi Asano; Osamu Kobori; Tetsuya Shiraishi; Emi Ito; Michiko Nakazato; Akiko Nakagawa; Masaomi Iyo; Eiji Shimizu
Journal:  BMC Res Notes       Date:  2013-02-28

6.  Long-term administration of escitalopram in patients with social anxiety disorder in Japan.

Authors:  Satoshi Asakura; Taiji Hayano; Atsushi Hagino; Tsukasa Koyama
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-22       Impact factor: 2.570

7.  Korean Guidelines for the Pharmacological Treatment of Social Anxiety Disorder: Initial Treatment Strategies.

Authors:  Hyungkun Yoon; Dong Jae Oh; Ho-Suk Suh; Kyoung-Uk Lee; Se-Won Lim; Jun-Yeob Lee; Jong-Chul Yang; Jae-Hon Lee; Juwon Ha; Bun-Hee Lee; Seung-Gul Kang; Ho-Kyoung Yoon; Jihyun Moon; Seung-Min Bae; Youngdo Kwon; Hyun-Chung Kim; Kang Seob Oh
Journal:  Psychiatry Investig       Date:  2017-11-29       Impact factor: 2.505

8.  Concomitant treatment with sertraline and social skills training improves social skills acquisition in social anxiety disorder: A double-blind, randomized controlled trial.

Authors:  Marcio Bernik; Fabio Corregiari; Mariangela Gentil Savoia; Tito Paes de Barros Neto; Cristiane Pinheiro; Francisco Lotufo Neto
Journal:  PLoS One       Date:  2018-10-29       Impact factor: 3.240

9.  Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials.

Authors:  Xinyuan Li; Yanbo Hou; Yingying Su; Hongping Liu; Beilin Zhang; Shaokuan Fang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.